BCM
CSTL icon

Bridgeway Capital Management’s Castle Biosciences CSTL Stock Holding History

Bridgeway Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.26M Buy
255,184
+8,264
+3% +$271K 0.13% 231
2025
Q4 		$9.61M Buy
246,920
+69,740
+39% +$2.25M 0.2% 147
2025
Q3 		$4.03M Buy
177,180
+136,430
+335% +$2.77M 0.09% 314
2025
Q2 		$832K Buy
+40,750
New +$754K 0.02% 685

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's CSTL Position: Q1 2026 in Review

Bridgeway Capital Management increased its Castle Biosciences (CSTL) stake by 3.3% in Q1 2026, buying an estimated $271K and bringing the position to 255,184 shares worth $6.26M. The position accounts for 0.13% of the portfolio, ranked #231.

Bridgeway Capital Management first reported a position in CSTL in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.61M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Bridgeway Capital Management held 255,184 shares of Castle Biosciences worth $6.26M as of Q1 2026.
  • Bridgeway Capital Management bought 8,264 Castle Biosciences shares in Q1 2026, an estimated $271K.
  • Castle Biosciences made up 0.13% of Bridgeway Capital Management's portfolio in Q1 2026, its #231 holding.
  • Bridgeway Capital Management first reported a position in Castle Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Bridgeway Capital Management's Castle Biosciences position peaked at $9.61M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.